Prevymis (Letermovir)

Prevymis (Letermovir)

Prevymis

Letermovir

Tablet: 240 mg; 480 mg and Injection: 240 mg/12 mL (20 mg/mL) or 480 mg/24 mL (20 mg/mL) in a single-dose vial

Merck

Medical Use

Prevymis is a CMV DNA terminase complex inhibitor used to prevent cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).

Recommended Dosage:

  • -Prevymis Tablets: Can be taken with or without food. Swallow the tablets whole.
  • -Prevymis Injection: Administered by intravenous infusion through a peripheral catheter or central venous line over 1 hour. Do not give as an intravenous bolus injection.

The recommended dosage is 480 mg, taken orally or intravenously once daily. Start treatment between Day 0 and Day 28 post-transplantation (before or after engraftment) and continue until Day 100 post-transplantation.

Use Prevymis injection, which contains hydroxypropyl betadex, only for patients who cannot take oral medication. Switch to oral Prevymis as soon as possible. Both the injection and tablet forms can be used interchangeably without dosage adjustment, based on the healthcare provider’s discretion.

Dosage Adjustments with Cyclosporine:

  • -If Prevymis is taken with cyclosporine, reduce the Prevymis dose to 240 mg once daily.
  • -If cyclosporine is started after Prevymis, reduce the next Prevymis dose to 240 mg once daily.
  • -If cyclosporine is stopped after Prevymis, increase the next Prevymis dose to 480 mg once daily.
  • -If cyclosporine dosing is temporarily interrupted due to high levels, no adjustment to the Prevymis dose is needed.